Why the study?
The study evaluated outcomes in patients with non- or minimally calcified anatomy undergoing TAVR with self-expanding valves, regardless of anatomical features, including those with LVAD support.
Does TAVR reduce 5-year all-cause mortality and disabling stroke compared to SAVR in lower surgical risk patients?
Does TAVR reduce 5-year all-cause mortality and disabling stroke compared to SAVR in lower surgical risk patients?
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: